Centre Eases Medical Device Rules & Adds EU to Waiver List
Recently, the Union Ministry of Health and Family Welfare updated the Medical Devices Rules to streamline regulatory pathways across India. Specifically, these crucial reforms eliminate separate loan licences for outsourced sterilisation and add the European Union to the clinical investigation waiver list. Consequently, clinicians and hospitals will gain faster access to advanced global healthcare technologies. Moreover, these changes aim to cut administrative bottlenecks for domestic manufacturers.
Key Amendments to the Medical Devices Rules
Earlier, domestic manufacturers outsourcing product sterilisation had to secure an independent loan licence. However, the updated regulations remove this repetitive requirement if the partner sterilisation facility already holds a valid licence under the rules. Furthermore, this policy decision significantly reduces compliance costs, paperwork, and procedural delays for domestic companies. In addition, the government has provided a six-month transition period for updating product labels. Therefore, manufacturers can seamlessly incorporate new packaging requirements without disrupting supply chains.
European Union Inclusion in Clinical Trial Waivers
Under the revised Rule 63, the government added the European Union to its recognised regulatory jurisdictions. Previously, this waiver list included only the United States, United Kingdom, Australia, Canada, and Japan. Consequently, eligible medical devices approved in the European Union no longer require redundant local clinical investigations in India. This step directly aligns with the India-EU Free Trade Agreement signed earlier this year. As a result, European manufacturers face fewer entry barriers, which accelerates patient access to cutting-edge medical technologies.
Impact on Indian Healthcare and Device Ecosystem
Currently, India imports nearly 80 to 85 per cent of its total medical device requirements. During FY26, device imports grew by 17 per cent year-on-year to reach Rs 89,000 crore. Thus, reducing regulatory friction ensures uninterrupted availability of high-risk, technology-intensive medical equipment. Simultaneously, local manufacturers can optimise operational efficiency by utilising specialized third-party sterilisation facilities. Ultimately, these progressive reforms enhance healthcare delivery while supporting India's expanding medtech industry. Medical professionals looking to expand their expertise can explore various multispecialty courses to stay updated with modern clinical standards.
Frequently Asked Questions
Q1: What major changes were introduced in the regulatory update?
The government eliminated the separate loan licence requirement for outsourced sterilisation and added the European Union to the clinical trial waiver list.
Q2: How does the European Union waiver benefit healthcare delivery?
The waiver allows EU-approved medical devices without Indian predicates to bypass duplicate local clinical investigations, accelerating patient access to proven therapies.
Q3: Is there a transition period for the new labelling requirements?
Yes, manufacturers have a six-month transition window to update packaging and ensure traceability for outsourced sterilisation sites.
References
- Centre eases Medical Devices rules, adds EU to waiver list - ETHealthworld
- Union Ministry of Health and Family Welfare Proposes Amendments to Medical Devices Rules, 2017 to Promote Ease of Doing Business - Press Information Bureau
- Medical Devices (Second Amendment) Rules, 2026 - Central Drugs Standard Control Organisation (CDSCO)
